Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are remarkably effective in patients with non-small cell lung carcinoma (NSCLC) harboring driver gene mutations and rearrangements. Crizotinib, a small-molecule TKI, has been demonstrated to be an efficacious drug against c-ros oncogene 1-rearranged NSCL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Masuda, Ken, Fujiwara, Yutaka, Shinno, Yuki, Mizuno, Takaaki, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Horinouchi, Hidehito, Yamamoto, Noboru, Ohe, Yuichiro
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6688037/
https://ncbi.nlm.nih.gov/pubmed/31463126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.07.44
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados